#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic lymphocytic leukaemia Erythema Henoch-Schonlein purpura Chronic graft versus host disease in intestine Chronic myeloid leukaemia (in remission) Hyperchylomicronaemia HER2 mutant non-small cell lung cancer Advanced systemic mastocytosis Ventricular fibrillation Soft tissue sarcoma Ichthyosis Anti-neutrophil cytoplasmic antibody positive vasculitis IgA nephropathy Hereditary angioedema Hypochondroplasia More trials…

    Learn about Rare Diseases

    Biotinidase deficiency – Treatment Medulloblastoma – Basic Information X-linked lymphoproliferative syndrome – Treatment Small intestine leiomyosarcoma Haemophilia B with anti factor IX – Diagnostics Primary biliary cholangitis – Basic Information Mucopolysaccharidosis II – Treatment Advanced systemic mastocytosis – Basic Information Paroxysmal nocturnal haemoglobinuria – Basic Information Systemic mastocytosis – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Metyrapone Bp Fidanacogene Elaparvovec SULBACTAM SODIUM Flortaucipir (18F) Tinlarebant L-Tryptophan Mometasone Furoate Monohydrate Apitegromab MB-001 Romosozumab Methionine Spartalizumab ANHYDROUS CALCIUM FOLINATE Soticlestat ICOTROKINRA Dmd06-Mab Dipyridamole Folic Acid Rbl012.2 Lt3001 More therapies…

    Learn about Your Condition

    Leukaemia Paraesthesia Neuropathic arthropathy Optic glioma Peripheral artery thrombosis Erythema multiforme Biliary tract operation Anaemia Anogenital warts Ocular melanoma Cardiac ventricular thrombosis Dysmenorrhoea Alpha-1 antitrypsin deficiency Immune-mediated myositis Scoliosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Oscar Lambret

Centre Oscar Lambret

3 Rue Frederic Combemale, Lille, 59000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Capecitabine
    • Fluorouracil
    • Folinic Acid
    Belgium Czechia France Germany Italy Lithuania +5

  • Study of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Abiraterone
    • Buclizine Hydrochloride
    • Codeine Phosphate
    France Germany Ireland Italy The Netherlands Poland +1

  • Study of Pucotenlimab with Becotatug Vedotin versus Becotatug Vedotin alone for patients with locally advanced head and neck squamous cell carcinoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • PUCOTENLIMAB
    France

  • Study on Niraparib and Dostarlimab for Patients with DNA Repair-Deficient or Platinum-Sensitive Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Dostarlimab
    • Niraparib
    France

  • Study of M9140 for Patients with Advanced Stomach Cancer

    Not recruiting

    1 1 1
    Austria France Germany Italy Spain

  • Study on Raludotatug Deruxtecan for Patients with Advanced or Metastatic Solid Tumors, Including Gynecological and Genitourinary Cancers

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Cervix carcinoma
    • Clear cell renal cell carcinoma
    • Endometrial cancer
    Investigated Drugs:
    • Raludotatug Deruxtecan
    Belgium Denmark France Italy Spain

  • Study of INBRX-106 and Pembrolizumab for First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer

    Not recruiting

    4 1 1
    Investigated Drugs:
    • HUMAN IGG1 HEXAVALENT ANTIBODY AGAINST TNFRSF4
    • Pembrolizumab
    Belgium Bulgaria France Italy Poland Romania +1

  • Study on Chemotherapy with Levoleucovorin, Capecitabine, and Folinic Acid for Patients Aged 70+ After Stage III Colon Cancer Surgery

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Colon cancer
    Investigated Drugs:
    • Capecitabine
    • Fluorouracil
    • Folinic Acid
    Belgium France

  • Study of Azenosertib and Niraparib for Patients with Platinum-Resistant Ovarian Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Ovarian cancer recurrent
    Investigated Drugs:
    • Azenosertib
    • Niraparib
    France

  • Study on the Safety and Effectiveness of Domvanalimab, Zimberelimab, and Quemliclustat in Adults with Advanced Upper Gastrointestinal Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastrointestinal carcinoma
    Investigated Drugs:
    • Calcium Folinate
    • Domvanalimab
    • Fluorouracil
    France
Previous Page
1 … 14 15 16 17 18 … 26
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!